ES3055824T3 - Plasminogen replacement therapy for plasminogen-deficiency - Google Patents

Plasminogen replacement therapy for plasminogen-deficiency

Info

Publication number
ES3055824T3
ES3055824T3 ES16861682T ES16861682T ES3055824T3 ES 3055824 T3 ES3055824 T3 ES 3055824T3 ES 16861682 T ES16861682 T ES 16861682T ES 16861682 T ES16861682 T ES 16861682T ES 3055824 T3 ES3055824 T3 ES 3055824T3
Authority
ES
Spain
Prior art keywords
plasminogen
activity
subject
glu
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16861682T
Other languages
English (en)
Spanish (es)
Inventor
Martin Robitaille
Karen Thibaudeau
Pierre Laurin
Stacy Plum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kedrion Biopharma Inc
Original Assignee
Kedrion Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kedrion Biopharma Inc filed Critical Kedrion Biopharma Inc
Application granted granted Critical
Publication of ES3055824T3 publication Critical patent/ES3055824T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16861682T 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency Active ES3055824T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
ES3055824T3 true ES3055824T3 (en) 2026-02-16

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16861682T Active ES3055824T3 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Country Status (24)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
DK (1) DK3370760T3 (enExample)
ES (1) ES3055824T3 (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
LT (1) LT3370760T (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
PL (1) PL3370760T3 (enExample)
PT (1) PT3370760T (enExample)
RS (1) RS67519B1 (enExample)
RU (1) RU2736831C2 (enExample)
SI (1) SI3370760T1 (enExample)
SM (1) SMT202500451T1 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
US12011455B2 (en) 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
US11129880B2 (en) * 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP3914288A1 (en) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2008026999A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
EP2451835A1 (en) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑

Also Published As

Publication number Publication date
US11291711B2 (en) 2022-04-05
RU2018120182A (ru) 2019-12-04
AU2016347863B2 (en) 2023-11-09
RS67519B1 (sr) 2025-12-31
SMT202500451T1 (it) 2026-01-12
FI3370760T3 (fi) 2025-12-05
IL258913A (en) 2018-06-28
ZA201802820B (en) 2019-07-31
CA3002915C (en) 2024-01-16
IL258913B (en) 2021-12-01
CN108289935A (zh) 2018-07-17
JP6878423B2 (ja) 2021-05-26
SI3370760T1 (sl) 2026-02-27
CA3002915A1 (en) 2017-05-11
RU2018120182A3 (enExample) 2020-04-27
BR112018008965A8 (pt) 2019-02-26
KR20180083348A (ko) 2018-07-20
EP3370760A4 (en) 2019-06-26
US20190231854A1 (en) 2019-08-01
LT3370760T (lt) 2025-12-29
AU2016347863A1 (en) 2018-06-07
PL3370760T3 (pl) 2026-03-23
KR102821400B1 (ko) 2025-06-18
WO2017077380A1 (en) 2017-05-11
MX2018005588A (es) 2018-11-09
DK3370760T3 (da) 2025-12-22
NZ742657A (en) 2024-04-26
BR112018008965A2 (pt) 2018-11-21
JP2018533589A (ja) 2018-11-15
TWI801331B (zh) 2023-05-11
PT3370760T (pt) 2025-12-03
EP3370760B1 (en) 2025-10-01
TW201722463A (zh) 2017-07-01
MY199581A (en) 2023-11-07
RU2736831C2 (ru) 2020-11-20
EP3370760A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
TWI801331B (zh) 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
Jude et al. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy
ES2618794T3 (es) El uso de fosfatasa alcalina para preservar la función renal
EA002496B1 (ru) Способы лечения состояний гиперкоагуляции или приобретенной недостаточности белка с
Roldán et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
ES2625153T3 (es) Factor II solo o en combinación con factores adicionales para el tratamiento de la hemostasia alterada asociada con una coagulopatía por dilución
US20220160847A1 (en) Method of preventing and/or treating a plurality of diseases
Aoki et al. A comparison of Ringer's lactate and acetate solutions and resuscitative effects on splanchnic dysoxia in patients with extensive burns
ES2331970T3 (es) Procedimiento para determinar el efecto antiinflamatorio de un peptido.
JPWO2020166557A1 (ja) 妊娠高血圧腎症の治療方法
US10441631B2 (en) Therapeutic agent for amniotic fluid embolism
ES2312966T3 (es) Uso del cd14 soluble para el tratamiento de enfermedades.
JPWO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
JP2014162789A (ja) 羊水塞栓症治療剤
Patel et al. Archives of Case Reports in Clinical Medicine
Shor et al. P139 Hyponatremia hypocalcemia and elevated creatine-kinase levels in a patient with SIADH secretion
HARRIS et al. 7 Fluid, electrolyte and acid-base balance
Booker Postoperative Care
Manole¹ et al. Risk factors for abdominal compartment syndrome in trauma–A review
Eksteen The association between fibrinolysis markers and body composition in black adults in the North West Province of South Africa